This report is being filed due to worsening heart failure with recurrent mitral regurgitation, deemed device related and requiring treatment.Crd_1002 - expand g4 phase 1 and phase 2 study patient id: (b)(6).It was reported that on 08/19/2021, the patient presented with mixed mitral regurgitation (mr) with anterior and posterior leaflet prolapse and leaflet tethering.One mitraclip was successfully implanted, reducing the mr to grade 1+.There was no device deficiency.On (b)(6) 2024, the patient was admitted to the hospital with lower extremity edema and mild shortness of breath.Worsening congestive heart failure (chf) was diagnosed, treated with medications.During this hospitalization, mitral valve stenosis, severe mr, and tricuspid valve regurgitation with mild pulmonary hypertension were diagnosed.On (b)(6) 2024, the patient was admitted to the hospital for a scheduled right heart catheterization.Elevated filling pressures with evidence of acute heart failure exacerbation were reported.Medications were provided as treatment.
|
The device was not returned for analysis.A review of the lot history record revealed no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Based on available information, the cause of the reported heart failure, recurrent mitral regurgitation, mitral stenosis, hypertension, tricuspid regurgitation, swelling, and dyspnea were unable to be determined.The reported patient effects of mitral regurgitation, heart failure, mitral stenosis, hypertension, tricuspid regurgitation, edema, and dyspnea, as listed in the mitraclip system instructions for use, are known possible complications associated with mitraclip procedures.The reported hospitalization and medication required were results of case-specific circumstances.There is no indication of a product quality issue with respect to manufacture, design, or labeling.
|